TG 테라퓨틱스(TGTX)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $56.87 (+0.71%), 시가총액 $6.53B, PER 14.91.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
TG 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
TG 테라퓨틱스의 현재 주가는 $56.87 (+0.71%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
TG 테라퓨틱스의 시가총액은 약 $6.53B입니다. PER은 14.91입니다.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United…